Skip to main content
Clinical Trials/NCT05135533
NCT05135533
Completed
Not Applicable

Cranial-nerve Non-invasive Neuromodulation and Dynamic Balance in Chronic Stroke Survivors

Medical University of South Carolina1 site in 1 country53 target enrollmentAugust 28, 2023
ConditionsStroke

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Stroke
Sponsor
Medical University of South Carolina
Enrollment
53
Locations
1
Primary Endpoint
Change in gait speed
Status
Completed
Last Updated
8 months ago

Overview

Brief Summary

Portable Neuromodulation Stimulator (PoNS) is non-invasive stimulation device placed on the tongue to stimulate those brain regions understood to be important for maintaining balance. This research study aims to collect evidence that PoNS therapy along with balance training improves postural and walking stability post-stroke.

Registry
clinicaltrials.gov
Start Date
August 28, 2023
End Date
July 24, 2025
Last Updated
8 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Steven Kautz

Depertment Chair

Medical University of South Carolina

Eligibility Criteria

Inclusion Criteria

  • At least six months since the onset of Ischemic or hemorrhagic stroke.
  • Demonstrate residual paresis in the lower extremity (Fugl-Mayer lower extremity score \< 34).
  • Are able to provide informed consent demonstrated by their ability to weigh the consequences of participating versus not participating in the study.
  • Can walk at least 10 feet with and without assistive device.
  • Functional Gait Assessment score \<22.

Exclusion Criteria

  • Pre-existing neurological disorders.
  • Previous stroke affecting the other hemisphere .
  • Severe arthritis or orthopedic problems that limit passive range of motion.
  • Areas of recent bleeding or open wounds.
  • Lack normal sensation on the tongue.
  • Received treatment for cancer within the past year.
  • Non-removable metal orthodontic devices.
  • Oral health problems.
  • Are sensitive to nickel, gold or copper.
  • Chronic infectious diseases.

Outcomes

Primary Outcomes

Change in gait speed

Time Frame: Pre-treatment, midpoint at four weeks, and post-treatment at 12 weeks

Self-selected comfortable walking overground walking speed.

Change in balance

Time Frame: Pre-treatment, midpoint at four weeks, and post-treatment at at 12 weeks

Functional Gait Assessment (FGA) assesses stability during walking. The score ranges between 0 and 30 with lower scores indicative of poor dynamic balance.

Study Sites (1)

Loading locations...

Similar Trials